Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Explore the potential of CARv3-TEAM-E T cells in recurrent glioblastoma, a novel therapy showing promise with rapid tumor regression and no severe adverse effects in early clinical evaluation.
Oncology, Medical March 18th 2024
Clinical Advances in Hematology & Oncology
Epcoritamab represents a significant breakthrough in the treatment of Richter syndrome, showcasing promising results in patients who have exhausted other therapeutic avenues. Its unique bispecific action heralds a new era in hematologic malignancy management.
Hematology/Oncology March 18th 2024
This pivotal study demonstrates that the combination of enfortumab vedotin and pembrolizumab not only extends progression-free survival but also significantly improves overall survival rates in patients with untreated advanced urothelial carcinoma.
Oncology, Medical March 11th 2024
Oncology Learning Network
Explore the recent FDA approval of biweekly teclistamab dosing for multiple myeloma, a significant stride in offering personalized treatment schedules that cater to patient and clinician needs.
Hematology/Oncology March 4th 2024
MDLinx
Amtagvi’s approval introduces a novel approach in the treatment of advanced melanoma, employing patient-derived TIL-cell therapy to target tumors with precision, offering a beacon of hope for those with limited options.
Dermatology March 4th 2024
In a recent phase 2 trial, frexalimab, targeting the CD40-CD40L pathway, demonstrated a notable reduction in new gadolinium-enhancing T1-weighted lesions in patients with relapsing multiple sclerosis.
Neurology February 21st 2024